Ricardo Bruges Maya

We shared our experience in managing patients with #mesothelioma at the @INCancerologia; a great team effort. @rafa_p10 @BrugesMaya Alejandra Navarrete, Marcela Núñez link.springer.com/article/10.100…

Thank you for all your support! 🙏🏻🙏🏻

Updated data on TRUST-I and TRUST -II presented at the 2026 AACR Congress places Taletrectinib as the preferred agent for 1L ROS-1 lung cancer tumors. TRUST-I, unprecedented mPFS of 50 months in TKI-naive patients. See other amazing outcomes: ORR, DOR and toxicity profile. @edgardo_ny @OncologyInst @FLASCO_ORG

🚨 New ALK inhibitor on the horizon! Deulorlatinib (TGRX-326) shows promising activity in ALK+ NSCLC after 2nd-gen TKI failure (DRAGON phase II) 🎯 ORR: 43.7% 🧠 CNS ORR: 55.8% 🧬 G1202R: ORR 62.5% A compelling option emerging for resistant ALK+ disease. @OncoAlert @MedwatchKate @OncoReporte @ManuelDomine @MedicalwatchHQ

An amazing experience!!!thanks you all.. see you in Mexico 🇲🇽 2027 #esmo. Great discussions, thinking out of the boxes and the best evidence 😊 @curijoey @LizzySmyth1 @AndresC27622123 @Prof_Nadia_H @DrPatronus @angelica_onco @SMEOMX #ALAS

This is an important analysis in @JCO_ASCO by @FDAOncology reviewers evaluating and giving a regulatory perspective on the analysis of Overall Survival after crossover, particularly challenging when agents are very effective in the crossover. ascopubs.org/doi/pdf/10.120…

@fedelosco @zapatalaguadomd @myESMO @UroTarget @Blatam_urology @aaoncoclinica @ASCO @achoHematoYOnco Espectacular participación! Gracias por la generosidad en compartir conocimientos y experiencias!

Closing the most important meeting in LATAM Oncology! Thank you @Prof_Nadia_H @AndresC27622123 @curijoey @myESMO @LizzySmyth1 for the amazing support! Hope to see you soon in Colombia, your home.

ESMO LATAM is coming soon! I’m proud to be part! Get you place soon!! We will be in Bogotá on Apr 17-18!

@BourlonMaite @cdanicas @sohecsas @myESMO @JACOBOSOLANOC @INCancerologia @BrugesMaya @Linamtru @cloc_oncologia @SCUColombia @DrQuirogaMil @Fundacion_CTIC The next year will be in México!🇲🇽 🌮

@fedelosco @UroTarget @Blatam_urology @LACOG_group @ASCO @aaoncoclinica @achoHematoYOnco @raymanneh ESMO Summit is around the corner. It will be a great meeting.

La prescripción de medicamentos no es una acción tan independiente como se puede creer. Está influida por una serie de incentivos que impactan sobre la decisión del profesional de la salud. Por ello, junto a @Luistocaruncho y @jriascos84 adelantamos esta revisión de...

Proud of this publication. After adjusting for confounding factors, income inequality has a negative impact on breast cancer survival. @fcardioinfantil @Fundacion_CTIC

Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. Co-authored by @DrStish @alediazmd. Read the full article. brnw.ch/21wZViL #ProstateCancer #pcsm

Congrats @raymanneh

@INCancerologia @fcardioinfantil @FSFB_Salud Un gran logro del INC y una exaltación del valor de lo público cuando se maneja con criterios técnicos. Mil felicitaciones. @BrugesMaya @BallenDF

Coffee and reduced dementia risk. For all you coffee lovers out there, including me! "Good ideas start with Brainstorming. Great ideas start with coffee"!

Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing. Read the full article. brnw.ch/21wZGvo

Updated review on approaching acquired resistance in EGFR mutant NSCLC @ESMO_Open from Dr. @LeXiuning et al. Important to uncover mechanisms of resistance whenever possible - on target, off target, bypass. Rapidly evolving space. esmoopen.com/article/S2059-…

#GI26 with my friend and mentor @OncoNerd who shared real-world BTC data from our country. OS remains poor, even in early stages. ICI approval has raised awareness beyond advanced disease, which we hope will improve OS across all stages.